MiMedx Group, Inc. (NASDAQ:MDXG) is a company that specializes in advanced wound care and therapeutic biologics. It focuses on developing and distributing products derived from human placental tissue, which are used in various medical applications. The company operates in a competitive landscape with peers like AxoGen, Inc., MacroGenics, Inc., Enanta Pharmaceuticals, Inc., Protagonist Therapeutics, Inc., and Omeros Corporation.
MiMedx Group, Inc. showcases a Return on Invested Capital (ROIC) of 16.73%, which is significantly higher than its Weighted Average Cost of Capital (WACC) of 11.20%. This results in a ROIC to WACC ratio of 1.49, indicating efficient capital utilization. The company is generating returns that exceed its cost of capital, a positive indicator for investors.
In contrast, AxoGen, Inc. has a ROIC of -3.91% and a WACC of 8.47%, leading to a negative ROIC to WACC ratio of -0.46. This suggests that AxoGen is not generating sufficient returns to cover its cost of capital, highlighting a less efficient use of capital compared to MiMedx.
Similarly, MacroGenics, Inc. reports a ROIC of -49.08% against a WACC of 8.88%, resulting in a ROIC to WACC ratio of -5.53. This further emphasizes the challenges faced by MacroGenics in generating returns above its cost of capital, unlike MiMedx.
Other peers like Enanta Pharmaceuticals, Inc., Protagonist Therapeutics, Inc., and Omeros Corporation also exhibit negative ROIC to WACC ratios, with figures of -3.54, -1.79, and -7.66 respectively. These metrics underscore MiMedx Group, Inc.'s superior capital efficiency in comparison to its peers.
